Who owns BRIDGEBIO PHARMA INC?
- CUSIP Number: 10806xab8
Tip: Access positions for across all investors
Analyze quarterly positions in Bridgebio Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Bridgebio Pharma stock
Who bought or sold BRIDGEBIO PHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Wolverine Asset Management | 82M | $148M | 80% | Mar 2026 |
|
| Linden Advisors | 78M | $148M | 0% | Dec 2025 |
|
| Steelhead Partners | 70M | $127B | 100% | Mar 2026 |
|
| Capstone Investment Advisors | 54M | $98M | 78% | Mar 2026 |
|
| Lazard Asset Management | 35M | $638k | -16% | Mar 2026 |
|
| Millennium Management | 25M | $44M | 17% | Mar 2026 |
|
| FMR | 22M | $42M | 256% | Dec 2025 |
|
| Graham Capital Management | 22M | $40M | 0% | Mar 2026 |
|
| 683 Capital Management | 22M | $39M | 0% | Mar 2026 |
|
| Aristeia Capital | 19M | $33M | 85% | Mar 2026 |
|
| Tenor Capital Management | 15M | $27M | -62% | Mar 2026 |
|
| M&G | 12M | $21M | 14% | Mar 2026 |
|
| State Street Corporation | 12M | $22M | 17% | Dec 2025 |
|
| DeepCurrents Investment Group | 9.5M | $17M | 100% | Mar 2026 |
|
| BlackRock | 8.9M | $16M | 28% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 7.4M | $13M | 2% | Mar 2026 |
|
| Camden Asset Management | 7.2M | $13B | 100% | Mar 2026 |
|
| Bnp Paribas Investment Partners | 3.2M | $6.0M | 100% | Dec 2025 |
|
| State of Wisconsin Investment Board | 3.0M | $5.7M | 0% | Dec 2025 |
|
| Amundi | 2.3M | $4.1k | 0% | Mar 2026 |
|
| Lord, Abbett & Co | 1.9M | $3.4M | -85% | Mar 2026 |
|
| Union Bancaire Privee, UBP SA | 1.8M | $2.6M | 62% | Mar 2026 |
|
| Agf Management | 1.0M | $1.8M | 0% | Mar 2026 |
|
| Universal- Beteiligungs- und Servicegesellschaft mbH | 721k | $1.3M | -76% | Mar 2026 |
|
| Palisade Capital Management | 664k | $1.3M | -27% | Dec 2025 |
|
| Calamos Advisors | 543k | $982k | 10% | Mar 2026 |
|
| SSI Investment Management | 398k | $716k | -29% | Mar 2026 |
|
| Goldman Sachs Group | 395k | $710k | 100% | Mar 2026 |
|
| Wells Fargo & Company | 371k | $669k | 0% | Mar 2026 |
|
| Advent Capital Management | 300k | $541k | 0% | Mar 2026 |
|
| Jane Street | 300k | $539k | 100% | Mar 2026 |
|
| GAMCO Asset Management | 300k | $566k | 0% | Dec 2025 |
|
| SG Americas Securities | 98k | $18M | 63% | Mar 2026 |
|
| Russell Investments | 69k | $125k | -57% | Mar 2026 |
|
| Calamos Wealth Management | 62k | $112k | 2% | Mar 2026 |
|
| Barclays | 46k | $87k | 188% | Dec 2025 |
|
| Nomura Holdings | 28k | $2.1M | 741% | Mar 2026 |
|
| ADAR1 Capital Management | 20k | $3.6M | 100% | Mar 2026 |
|
| Wiley Bros.-aintree Capital | 16k | $30k | 100% | Dec 2025 |
|
| Traub Capital Management | 10k | $18k | 0% | Mar 2026 |
|
| Pnc Financial Services | 2.0k | $360k | 0% | Mar 2026 |
|
| Northwestern Mutual Wealth Management Company | 1.0k | $1.8k | 0% | Mar 2026 |
|
| Jones Financial Companies, L.L | 1.0k | $1.9k | 0% | Dec 2025 |
|
Who sold out of Bridgebio Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Weiss Asset Management LP[1 | Dec 2025 | 51M | $96M |
| Citadel Advisors | Dec 2025 | 45M | $84M |
| Ing Investment Management | Dec 2025 | 24M | $46M |
| Balyasny Asset Management | Dec 2025 | 15M | $28M |
| Ares Systematic Credit | Dec 2025 | 500k | $948k |
| Bank of New York Mellon | Dec 2025 | 300k | $567k |
| Jpmorgan Chase & Co | Sep 2025 | 299k | $418k |
| Royal Bank of Canada | Sep 2025 | 286k | $286k |
| Leucadia National Corporation | Dec 2025 | 259k | $489k |
| Goss Wealth Management | Dec 2025 | 19k | $36k |
| UBS Group | Dec 2025 | 1.0k | $1.9k |